PHAT

Phathom Pharmaceuticals, Inc.

Healthcare
Biotechnology
$676M market cap

Forecast run · Sep 14, 2026Upside rank 751 of 3,136

Model Signal

ForecastQ Daily Probabilities

49.8%

37.2%

30.5%

Analyst Consensus

Recommendation2.11/5 Buy

Last price$8.36

Price target$17.60

Implied move+110.5%

Analysts9

ForecastQ Portfolios

PHAT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.